{"id":"matching-vehicle-solution","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108661","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This product appears to be a placebo or vehicle control used in Phase 3 clinical trials, formulated to match the physical and chemical characteristics of an active drug without containing the therapeutic agent itself. It is used to enable blinded comparisons and establish the efficacy of the actual investigational drug by controlling for non-specific effects of the formulation.","oneSentence":"Matching Vehicle Solution is a pharmaceutical vehicle or excipient formulation designed to match the properties of an active pharmaceutical ingredient for comparative or control purposes in clinical trials.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:49:44.059Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05608681","phase":"PHASE1, PHASE2","title":"A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).","status":"RECRUITING","sponsor":"Eupraxia Pharmaceuticals Inc.","startDate":"2023-03-31","conditions":"Eosinophilic Esophagitis","enrollment":117},{"nctId":"NCT07447141","phase":"PHASE1","title":"DBM-1152A Inhalation Solution in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2023-12-24","conditions":"Health, Health Adult Subjects","enrollment":44},{"nctId":"NCT07439419","phase":"PHASE1","title":"DBM-1152A Inhalation Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2024-08-18","conditions":"Healthy","enrollment":20},{"nctId":"NCT07412587","phase":"NA","title":"Therapeutic Potential of Topical Latanoprost Acid in Hair Loss - Pilot, Proof-of-concept Study","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2015-07-08","conditions":"Androgenetic Alopecia (AGA), Telogen Effluvium, Female Pattern Hair Loss, Androgenic Alopecia","enrollment":29},{"nctId":"NCT06890039","phase":"PHASE2","title":"A-TANGO Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"Yaqrit Ltd","startDate":"2025-09-01","conditions":"Acute-On-Chronic Liver Failure, Alcoholic Hepatitis, Liver Cirrhosis, Alcoholic","enrollment":78},{"nctId":"NCT04030962","phase":"PHASE1, PHASE2","title":"A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-03-04","conditions":"Dry Eye Disease, Dry Eye Syndrome","enrollment":292},{"nctId":"NCT06678399","phase":"PHASE1, PHASE2","title":"Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Kelifarma","startDate":"2025-04-01","conditions":"Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery","enrollment":91},{"nctId":"NCT06622824","phase":"PHASE2, PHASE3","title":"To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Kintor Pharmaceutical Inc,","startDate":"2024-10-15","conditions":"Androgenetic Alopecia (AGA)","enrollment":756},{"nctId":"NCT04909450","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects","status":"COMPLETED","sponsor":"Claris Biotherapeutics, Inc.","startDate":"2021-08-24","conditions":"Neurotrophic Keratitis","enrollment":131},{"nctId":"NCT05180500","phase":"PHASE1","title":"Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis","status":"COMPLETED","sponsor":"Sharon Hillier","startDate":"2022-03-15","conditions":"COVID-19, Pharmacokinetics, Safety","enrollment":50},{"nctId":"NCT02022215","phase":"PHASE2","title":"Efficacy and Safety Study of ME1111 in Patients With Onychomycosis","status":"COMPLETED","sponsor":"Meiji Seika Pharma Co., Ltd.","startDate":"2013-12-19","conditions":"Onychomycosis","enrollment":304},{"nctId":"NCT05039359","phase":"PHASE3","title":"Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation","status":"TERMINATED","sponsor":"InCarda Therapeutics, Inc.","startDate":"2022-04-26","conditions":"Paroxysmal Atrial Fibrillation","enrollment":54},{"nctId":"NCT04511650","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019","status":"TERMINATED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2020-10-21","conditions":"COVID-19, Acute Respiratory Distress Syndrome (ARDS)","enrollment":31},{"nctId":"NCT05283161","phase":"PHASE2, PHASE3","title":"CBD (Cannabidiol)/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann)","status":"UNKNOWN","sponsor":"FG Brasil LTDA","startDate":"2022-04-15","conditions":"Fibromyalgia","enrollment":40},{"nctId":"NCT03131167","phase":"PHASE1","title":"Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Shire","startDate":"2017-05-10","conditions":"Primary Open-angle Glaucoma (POAG), Ocular Hypertension","enrollment":63},{"nctId":"NCT04762355","phase":"PHASE1","title":"Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Clementia Pharmaceuticals Inc.","startDate":"2018-08-30","conditions":"Dry Eye Disease","enrollment":48},{"nctId":"NCT04256655","phase":"PHASE1","title":"Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU Patients","status":"WITHDRAWN","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2020-12-01","conditions":"Phenylketonurias","enrollment":""},{"nctId":"NCT04085666","phase":"PHASE1","title":"Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)","status":"COMPLETED","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2019-06-01","conditions":"Phenylketonuria","enrollment":18},{"nctId":"NCT04115462","phase":"NA","title":"A Relation of Morphine-induced Itch and Pain Processing","status":"COMPLETED","sponsor":"Aalborg University","startDate":"2020-01-15","conditions":"Morphine, Itch","enrollment":24},{"nctId":"NCT03469336","phase":"PHASE1","title":"Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-04-24","conditions":"Psoriasis","enrollment":18},{"nctId":"NCT03606057","phase":"PHASE1","title":"A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-07-13","conditions":"Healthy","enrollment":188},{"nctId":"NCT04284514","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution","status":"COMPLETED","sponsor":"Aerpio Therapeutics","startDate":"2019-05-02","conditions":"Ocular Hypertension, Primary Open Angle Glaucoma","enrollment":91},{"nctId":"NCT04247230","phase":"PHASE1","title":"Study to Determine the Effect of a Newly Formulated Tetracaine Product PET500 on Penile Skin Sensation","status":"COMPLETED","sponsor":"Futura Medical Developments Ltd.","startDate":"2008-09-03","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT03821415","phase":"PHASE2","title":"Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Redwood Pharma AB","startDate":"2019-01-18","conditions":"Dry Eye Syndromes","enrollment":104},{"nctId":"NCT03665194","phase":"PHASE1","title":"A Study to Investigate the Effects of Cortexolone 17α-propionate (and Its Metabolites) on Healthy Volunteers' Heart","status":"COMPLETED","sponsor":"Cassiopea SpA","startDate":"2018-06-06","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT01254604","phase":"PHASE3","title":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":190},{"nctId":"NCT02224521","phase":"PHASE1","title":"GSK2190915A - Bioavailability Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-20","conditions":"Asthma","enrollment":67},{"nctId":"NCT00933530","phase":"PHASE1","title":"A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers","status":"COMPLETED","sponsor":"Sirtris, a GSK Company","startDate":"2008-05","conditions":"Diabetes Mellitus, Type 2, Healthy Volunteer","enrollment":43},{"nctId":"NCT00574249","phase":"PHASE3","title":"Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-11","conditions":"Chronic Plaque Psoriasis","enrollment":730}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching Vehicle Solution","genericName":"Matching Vehicle Solution","companyName":"Meiji Seika Pharma Co., Ltd.","companyId":"meiji-seika-pharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}